COMMUNIQUÉS West-GlobeNewswire

Tauriga Sciences, Inc. to Launch an E-Commerce Site to Coincide with the Commercial Launch of its Cannabis/CBD Infused Chewing Gum Product Line

07/01/2019 - 14:00

NEW YORK, NY, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of [...]

Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy

07/01/2019 - 14:00

Preparing Three Lead Programs for MLD, ADA-SCID and WAS for Regulatory Filings Over the Next Three Years Recently Announced Clinical Proof-of-Concept in X-CGD Demonstrates Platform’s Transformative Potential Advancing [...]

CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results

07/01/2019 - 14:00

BRISBANE, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value [...]

Fertin Pharma’s Parent Company Acquires MedCan Pharma - Allowing Entry into Fast-growing Market for Cannabinoid Products

07/01/2019 - 11:46

VEJLE, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Claudio Bidco A/S (the “ Parent Company ”), the parent company of Fertin Pharma A/S (“ Fertin Pharma ”) has signed and closed the acquisition of MedCan Pharma A/S (“ [...]

Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue

07/01/2019 - 11:30

PLANO, Texas, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended [...]

Tecan to present at J.P. Morgan Healthcare Conference

07/01/2019 - 10:31

Männedorf, Switzerland, January 7, 2019 - The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will present at J.P. Morgan Healthcare Conference in San Francisco, USA, on January 10, 2019. The investor [...]

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

07/01/2019 - 10:00

– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an Orally Available, [...]

FIT Biotech Oy: Changes in FIT Biotech's Board of Directors

07/01/2019 - 08:56

FIT Biotech Oy Company release 7.1.2019 at 9:55 EET Changes in FIT Biotech's Board of Directors FIT Biotech Oy's ("Company", FITBIO: FN Finland) Chairman of the Board of Directors, Doctor Chitra Bharucha has resigned [...]

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

07/01/2019 - 08:31

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs Companies select two clinical-stage bispecific antibodies for ongoing collaboration Sanofi able to independently [...]

Sanofi et Regeneron restructurent leur collaboration de recherche et développement en immuno-oncologie

07/01/2019 - 08:31

Sanofi et Regeneron restructurent leur collaboration de recherche et développement en immuno-oncologie Les deux entreprises retiennent deux anticorps bispécifiques au stade clinique pour la poursuite de leur [...]

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

07/01/2019 - 08:00

LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37 th Annual JP Morgan [...]

Saniona completes treatment in Phase 2a Prader-Willi syndrome trial and initiates open label extension study

07/01/2019 - 08:00

PRESS RELEASE January 7, 2019 Saniona (OMX: SANION), a biotech company focused on CNS and eating disorders, today announced that it has completed the 3-month treatment period in adolescent patients in the second part of [...]

Galapagos starts first Phase 1 trial with Toledo compound

07/01/2019 - 07:31

Novel target class with dual action in inflammatory disorders Discovered and validated on Galapagos' target discovery platform Fully owned and proprietary Mechelen, Belgium; 7 January 2019, 7.30 CET - Galapagos NV ( [...]

Irina Maligina: Changes in the Board of Olmafarm, the main shareholder of Olainfarm, are illegal and will not affect the work of JSC Olainfarm

07/01/2019 - 07:30

Commenting on the recently registered changes in the Board of JSC Olainfarm's largest shareholder – SIA Olmafarm, the Deputy Chairman of the Supervisory Board of JSC Olainfarm, Irina Maligina, informs of the following: [...]

Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018

07/01/2019 - 07:15

Basel, Switzerland, January 07, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the unaudited preliminary revenue for the financial year 2018. Total revenue is expected to increase by 31% over 2017 to [...]

Biocartis Group NV: Biocartis Announces Achieving its 2018 Key Business Objectives

07/01/2019 - 07:02

PRESS RELEASE: REGULATED INFORMATION - INSIDE INFORMATION 7 January 2019, 07:01 CET Biocartis Announces Achieving its 2018 Key Business Objectives Mechelen, Belgium, 7 January 2019 - Biocartis Group NV (the 'Company' or [...]

VALNEVA Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

07/01/2019 - 07:01

Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile [...]

VALNEVA annonce des résultats intermédiaires de Phase 1 positifs pour son candidat vaccin contre le Chikungunya

07/01/2019 - 07:01

Valneva annonce des résultats intermédiaires de Phase 1 positifs pour son candidat vaccin contre le Chikungunya Les résultats intermédiaires de Phase 1 ont montré un excellent profil d'immunogénicité après une seule [...]

Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus

07/01/2019 - 07:01

Allschwil, Switzerland - January 7, 2019 Idorsia Ltd (SIX: IDIA) today announced that the first patient has been enrolled into a multiple-dose study to evaluate the efficacy and safety of cenerimod, a selective S1P 1 [...]